Genoray Co

Genoray Co Equity

The The Equity of Genoray Co (122310.KQ) as of Nov 7, 2026 is 84.49 B KRW. In the previous year, The Equity was 85.89 B KRW — a change of -1.63% (lower).

Equity

84.49 BKRW

YoY

-1.63%

Last updated:

In 2025, Genoray Co's equity was 84.49 B KRW, a -1.63% increase from the 85.89 B KRW equity in the previous year.

The Genoray Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
44.97 B KRW
Jan 1, 2019
59.59 B KRW
Jan 1, 2020
66.53 B KRW
Jan 1, 2021
78.82 B KRW
Jan 1, 2022
87.96 B KRW
Jan 1, 2023
95.35 B KRW
Jan 1, 2024
85.89 B KRW
Jan 1, 2025
84.49 B KRW
The Genoray Co Equity history
YEAREquityYoY
84.49 BKRW-1.63%
85.89 BKRW-9.92%
95.35 BKRW+8.39%
87.96 BKRW+11.60%
78.82 BKRW+18.47%
66.53 BKRW+11.65%
59.59 BKRW+32.49%
44.97 BKRW+85.09%
24.30 BKRW+64.16%
14.80 BKRW+30.36%
11.35 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genoray Co Stock analysis

What does Genoray Co do? Genoray Co Ltd, based in Seongnam, South Korea, operates in the Health Care sector, specializing in medical and dental digital x-radiation systems. The company, listed on 28 May 2018, serves through two segments: Medical, focusing on mobile C-arm and mammography equipment, and Dental, offering panoramic, cephalometry, 3D CT, and portable X-ray solutions. Genoray Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Genoray Co's Equity

Genoray Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Genoray Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Genoray Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Genoray Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Genoray Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Genoray Co stock

The Equity of Genoray Co is 84.49 B KRW in 2025.

The Equity of Genoray Co changed from 85.89 B KRW to 84.49 B KRW, representing a -1.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Genoray Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Genoray Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Genoray Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genoray Co